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Context: Familial partial lipodystrophy type 1 (FPLD1) is an extreme form of central adiposity, with
peripheral lipodystrophy associated with severe manifestations of the metabolic syndrome, often
poorly responsive to standard therapeutic approaches. Bodymass index in FPLD1 varies but, inmany
cases, is below the level at which metabolic surgery is usually considered as a therapeutic option.
Design:We detailed the metabolic response to gastric bypass surgery of three patients with FPLD1,
refractory to medical therapy.
Results: Roux-en-Y gastric bypass (RYGB)was associatedwithweight loss and substantial improvements
in glycemic control and insulin sensitivity. All three patients were able to stop using insulin. Glucose
tolerance testing in one patient demonstrated an increase in L-cell–derived gut hormone responses
postoperatively.
Conclusion: RYGB surgery substantially improved glycemic control in three patientswith FPLD1, two
of whom had bodymass indices below 30 kg/m2. RYGB should be considered in patients with partial
lipodystrophyandrefractorymetabolicdisease. (J ClinEndocrinolMetab102: 3616–3620, 2017)
F amilial partial lipodystrophy type 1 (FPLD1) is char-acterized by central fat accumulation, reduced pe-
ripheral subcutaneous adipose tissue, and ectopic fat
deposition (1). The metabolic sequelae of FPLD1 can be
severe and include insulin-resistant type 2 diabetes,
dyslipidemia, nonalcoholic fatty liver disease (NAFLD),
and hyperandrogenism. Patients with FPLD1 have long
posed a treatment challenge, with current approaches
targeting metabolic complications of ectopic fat de-
position using similar strategies to those used in obese
patients with diabetes (2). Recombinant leptin therapy is
very effective in patientswith generalized lipodystrophy and
to a lesser extent in other forms of partial lipodystrophy, but
leptin levels in most patients with FPLD1 are well above
current thresholds (4 to 10mg/L) for leptin therapy (3).Here
we report on the metabolic outcomes of gastric bypass
surgery in three patients with FPLD1.
Materials and Methods
Participants were assessed at the National Severe Insulin Re-
sistance Service, Cambridge University Hospital, and further
evaluated at the National Institute for Health Research/
Wellcome Trust Clinical Research Facility. Ethical approval
was obtained from the East of England-Cambridge Research
Ethics Committee, and participants have consented to the use of
data for scientific publication. Dual-energy X-ray absorpti-
ometry (DEXA) imaging was undertaken on Lunar iDXA or
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Lunar Prodigy (GE Health Care), with specialized assays com-
pleted at the Core Biochemical Assay Laboratory, University of
Cambridge.
Results
Patient A
A 49-year-old female attending the National Severe
Insulin Resistance Service had originally presented at age
32 years with gestational diabetes, which persisted
postpartum. She developed central adiposity during
puberty. She has a positive family history for diabetes
(Supplemental Fig. 1). Prior to referral, her glycemia had
been managed with metformin (stopped due to gastro-
intestinal intolerance) and gliclazide, followed by insulin
therapy and exenatide. Examination and DEXA imaging
(Supplemental Fig. 2) confirmed central adiposity with
peripheral lipodystrophy. Biochemical tests were con-
sistent with those typical of patients with partial
lipodystrophy. Therefore, having excluded mutations in
LMNA (laminA/C) andPPARG (peroxisone proliferator
activated receptor g), a diagnosis of FPLD1 was made. A
low-calorie diet was introduced, but glycemic control
remained suboptimal despite large insulin doses. Tri-
glyceride levels were modestly elevated (.2 mmol/L)
(Table 1). Referral for gastric bypass surgery was made
at the patient’s request on clinical grounds at age 53. At
this time, her body mass index (BMI) was 27.4 kg/m2.
Blood glucose readings fell within days of surgery, re-
quiring the cessation of all medication (Supplemental
Fig. 3), with a corresponding fall in hemoglobin A1c. Oral
glucose tolerance testing was undertaken before and
3 months after surgery (Fig. 1). Postoperatively, glucose
tolerance was greatly improved, and this was associated
Table 1. Impact of RYGB on Anthropometric and Biochemical Measurements
Patient A Patient B Patient C
Preoperative
Postoperative
3 Months Preoperative
Postoperative
3 Months
Postoperative
40 Months Preoperative
Postoperative
18 Months
Ref
Range
BMI (kg/m2) 27.4 21.7 32.4 24.7 26.8 29.7 22.9
Body fat (%)a 49.1 42.9 37 24.5 NA NA 28
Android:gynoid ratio 1.46 1.28 1.53 1.38 NA NA 1.16
Fat mass ratiob 1.63 1.56 1.80 1.83 NA NA 1.45
Hepatic fat fraction (%)c 7 7 6 3 3.2 20 3.2
HbA1c (mmol/mol) 75 54 118 50 47 113 48 36–45
HbA1c (%) 9.0 7.1 12.9 6.7 6.3 12.5 6.5 4.9–6.3
Leptin (ng/mL) 59.1 7.6 15.6 3 9.8 20.9 6.2 d
Adiponectin (g/mL) 5.9 8 3.8 4.6 7.1 4.3 16.5 e
Leptin/adiponectin ratio
(ng/mg)
10.0 1.0 4.1 0.7 1.3 4.9 0.4
Insulin (pmol/L) 67 18 67 35 29 132 33 0–80
C-peptide (pmol/L) 608 312 890 662 774 1897 1210 170–960
Cholesterol (mmol/L) 8.2 7.6 4.9 2.6 3.7 5.3 4.1
Low-density lipoprotein
(mmol/L)
6.3 5.5 3.4 1.4 1.8 2.6 1.8
Triglyceride (mmol/L) 2 2.8 1.1 0.5 0.7 3.5 1.9
High-density lipoprotein
(mmol/L)
1.0 0.8 1.0 1.0 1.5 1.1 1.4
Albumin (g/L) 37 34 38 38 37 38 35 35–50
Bilirubin (umol/L) 11 8 6 6 6 5 3 0–20
Alk phos (U/L) 106 111 126 72 47 132 96 30–130
Alanine aminotransferase
(U/L)
18 18 27 32 26 51 22 7–40
GGT (U/L) 21 11 28 19 10 66 11 0–37
TSH (mU/L) 2.3 2.5 1.4 1 1.3 1.0 1.2 0.35–5.55
FT4 (pmol/L) 14.2 NA 15.8 12.8 11.5 15.3 10.8 10.0–19.8
Insulin dose (unit/d) 110–200 0 80–120 0 0 20–40 0
Additional medical therapy Telmisartan Metformin Metformin Metformin Metformin
Sitagliptin Simvastatin Simvastatin Gliclazide
Simvastatin Liraglutide
Ramipril Losartan
Abbreviations: Alk phos, alkaline phophatase; FT4, free T4; GGT, gamma-glutamyl transferase; HbA1c, hemoglobin A1c; NA, not available; TSH, thyroid-
stimulating hormone.
aDEXA.
bFat mass ratio represents percentage trunk fat compared with legs.
cMagnetic resonance imaging.
dLeptin ref range (ng/mL) (female): BMI 25 kg/m2 = 2.5 to 24.4; BMI 25 to 30 kg/m2 = 8.6 to 38.9; BMI 30 to 35 kg/m2 = 14.9 to 60.9; BMI.35 kg/m2 =
27.7 to 113.6.
eAdiponectin ref range (mg/mL) (female): BMI 25 kg/m2 = 4.4 to 17.7; BMI 25 to 30 kg/m2 = 3.5 to 15.5; BMI 30 to 35 kg/m2 = 2.6 to 14.9; BMI.35 kg/m2 =
2.6 to 17.1.
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with dramatically increased L-cell–derived satiety hor-
mones glucagonlike peptide-1 (GLP-1) and peptide YY
(PYY).Glucose-dependent insulinotropic polypeptide levels
were unchanged. Consistent with the reduction in adiposity
and fasting glucose, fasting insulin levels were markedly
reduced, whereas the incremental insulin response to the
glucose load was similar to that found preoperatively, de-
spite the much lower postprandial glucose levels.
Patients B and C
Two further female patients were diagnosed with
FPLD1 following the exclusion of hypercortisolism and
pathogenic PPARG variants. Both displayed the classical
clinical features of FPLD1. Patient B had hypertension,
dyslipidemia, NAFLD, and secondary diabetes requir-
ing .180 units of insulin daily. She gained weight in
parallel with increasing insulin doses. A structuredweight
management program achieved modest weight loss, but
HbA1c remained .100 mmol/mol (11.3%), and reti-
nopathy and nephropathy had developed. Patient C
also experienced NAFLD, dyslipidemia, and poorly
controlled diabetes despite multiple
glucose-lowering therapies. She did
respond favorably (weight loss of
4.6 kg and improved glycemic control)
to a low-energy liquid diet but was
unable to sustain the weight loss. Both
patients were referred for Roux-en-Y
gastric bypass (RYGB) surgery. Patient
B was age 44 and obese with a BMI of
32.4 kg/m2. Postoperatively, her in-
sulin was stopped due to dramatic
improvements in blood glucose, and
she is currently well controlled on met-
formin alone. At age 53 with a BMI of
29.7 kg/m2, patient C underwent gastric
bypass surgery that resulted in a dramatic
improvement in diabetes control and
cessation of all glucose-lowering medi-
cation. In addition to weight loss, both
patients experienced a reduction in he-
patic fat and fasting insulin levels
(Table1). PatientBhadanuncomplicated
course and remains well 40 months post
RYGB. Patient C developed a gastric
ulcer at 18 months postoperatively and
reported dental caries, but she too re-
mains metabolically well.
Discussion
FPLD1 is a disorder characterized by
reduced peripheral adipose tissue ex-
pandability (1). This is thought to engender a mismatch
between the need and capacity to buffer excess energy
intake leading to insulin resistance and its associated
metabolic problems. The mainstay of therapy, although
challenging to achieve, is reduced caloric intake (Sup-
plemental Fig. 4) (2). Patients with FPLD1 who lose
weight manifest significant metabolic improvements.
However, they struggle to sustain this, perhaps in part
due to relative leptin deficiency secondary to peripheral
lipodystrophy. RYGB, previously viewed solely as a
bariatric procedure, has emerged as effective therapy in
the management of metabolic dysfunction in obese in-
dividuals, raising the question of its role in nonobese
individuals with deranged glycemic control.
We assessed the impact of RYGB on fat mass in three
patients with FPLD1; all manifested substantial sustained
weight loss, and DEXA imaging demonstrated a reduc-
tion in fat across all body compartments. A marked
decline in android fat mass was evident, owing to
the pathological distribution of fat observed in
FLPD1 (Fig. 2). Our patients reported reduced hunger
Figure 1. The pancreatic and enteroendocrine hormonal responses of patient A to a 50-g
oral glucose tolerance test preoperatively (black line) and 3 months following RYGB surgery
(dashed line). Glucose tolerance improved postoperatively. GLP-1 and PYY response to
glucose load increased at 3 months, while glucose-dependent insulinotropic polypeptide was
largely unchanged.
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postoperatively, despite the postoperative drop in leptin
levels, and it is likely that this is the primary reason for
the beneficial impact of surgery on energy balance.
The precise basis for the appetitive changes that oc-
cur post RYGB surgery in all patient groups is a topic
of intense scientific activity, but the increased post-
prandial levels of GLP-1 and PYY3 through PPY36,
hormones with an anorectic effect, are likely to play an
important role.
The most dramatic clinical impact in all three patients
was on the poorly controlled type 2 diabetes that was
present preoperatively. The improvement in glycemic
control is consistent with that seen in obese individuals
with type 2 diabetes who undergo bariatric surgery (4) or
who sustain a period of negative energy balance due to
intense dietary restriction (5). Patients with FPLD1 are
frequently very insulin resistant, almost certainly due to
lipotoxicity in insulin-responsive tissues such as muscle
and liver, which are responsible for a large component
of glucose clearance; this was reflected in the high in-
sulin doses and poor glycemic control of patients A and
B and in the high fasting insulin levels in patient C.
Measures of insulin resistance (fasting insulin and
leptin-adiponectin ratio) were markedly improved in all
three patients postoperatively, likely due to the re-
duction in lipotoxic load to insulin-responsive tissues
as a result of sustained negative energy balance. It is
possible that the increased GLP-1 levels had an addi-
tional impact on glycemic control through their incretin
effect, but the dramatically different fasting and post-
load glucose levels that were present pre- and post-
operatively in patient A make it impossible to comment
meaningfully on this.
Patient A did not have a marked elevation in hepatic
fat (at least as measured noninvasively) or in circulating
triglycerides, but these measures were more markedly
abnormal in patients B and C in whom the beneficial
impact of surgery on liver fat and circulating lipids was
more obvious.
All of our patients have remained
clinically well at follow-up; however,
patient C developed a gastric ulcer,
which was treated effectively with
medical therapy. Although serious
adverse events are uncommon fol-
lowing metabolic procedures, pa-
tients should be counseled on the
procedure risks and the requirement
for extended follow-up and nutri-
tional supplementation. To date,
RYGB has been the only metabolic
surgery reported in patients with
lipodystrophy, and it is unknown if
similar efficacy would be seen with other weight-
lowering procedures.
Conclusion
Reports of the use of RYGB in the management of
lipodystrophy are sparse. In addition to one previously re-
ported case in FPLD1, RYGB has been used in FPLD2
(LMNA) and FPLD4 [perlipin 1 (PLIN1)] monogenic
lipodystrophies (6–10). In our FPLD1 cases, RYGB
achieved glycemic targets where optimum medical ther-
apy had been unsuccessful, additionally reducing ectopic
fat deposition as a likely critical mediator of themetabolic
dysregulation observed in this condition. RYGB may be
an important adjunct to optimal medical management of
patients with FPLD1.
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